More tools:Markets·Screener·Research·Chat

Fortress Biotech, Inc. (FBIO) Financial Statements

Fortress Biotech, Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001V0GB64
XNAS · usd
2.71▼ 0.01 (-0.37%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close2.72
Day's Range2.67 – 2.75
52-Week Range2.18 – 4.53
Volume263.0K
Avg Volume599.0K
Share Statistics
Shares Outstanding
Employees78
ExchangeXNAS
Listed2011-11-17
Share count as of August 10, 2026
Loading Income Statement…
Key questions about Fortress Biotech, Inc. (FBIO)
What is Fortress Biotech, Inc.'s Market Cap?
Fortress Biotech, Inc.'s Market Cap is $99.7M, based on as-reported figures from SEC (XBRL) filings.
What is Fortress Biotech, Inc.'s Enterprise Value?
Fortress Biotech, Inc.'s Enterprise Value is -$61.9M, based on as-reported figures from SEC (XBRL) filings.
What is Fortress Biotech, Inc.'s Trailing P/E?
Fortress Biotech, Inc.'s Trailing P/E is 1.0×, based on as-reported figures from SEC (XBRL) filings.
What is Fortress Biotech, Inc.'s Price / Sales?
Fortress Biotech, Inc.'s Price / Sales is 1.5×, based on as-reported figures from SEC (XBRL) filings.
What is Fortress Biotech, Inc.'s EV / Revenue?
Fortress Biotech, Inc.'s EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Fortress Biotech, Inc.'s EV / EBITDA?
Fortress Biotech, Inc.'s EV / EBITDA is 2.5×, based on as-reported figures from SEC (XBRL) filings.
What is Fortress Biotech, Inc.'s Revenue (TTM)?
Fortress Biotech, Inc.'s Revenue (TTM) is $68.5M, based on as-reported figures from SEC (XBRL) filings.
What is Fortress Biotech, Inc.'s Net Income (TTM)?
Fortress Biotech, Inc.'s Net Income (TTM) is $103.4M, based on as-reported figures from SEC (XBRL) filings.
What is Fortress Biotech, Inc.'s EBITDA?
Fortress Biotech, Inc.'s EBITDA is -$24.6M, based on as-reported figures from SEC (XBRL) filings.
What is Fortress Biotech, Inc.'s Diluted EPS (TTM)?
Fortress Biotech, Inc.'s Diluted EPS (TTM) is 2.81, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
Product revenue, net
Other revenue
Net revenue
YoY growth+14.0%+22.1%+6.3%+20.5%
Operating expenses
Cost of goods - (excluding amortization of acquired intangible assets)
Amortization of acquired intangible assets
Research and development
Selling, general and administrative
Total operating expenses
% of revenue153.5%148.3%129.8%138.6%
Loss from operations
% of revenue-53.5%-48.3%-29.8%-38.6%
Other income (expense)
Interest income
Interest expense and financing fee
Gain on sale of priority review voucher, net of expenses——
Change in fair value of partner company derivative liability——
Gain (loss) on common stock warrant liabilities—
Gain from deconsolidation of subsidiary—
Other income (expense)
Total other income (expense)
Income (loss) before income tax expense
Income tax expense
Net income (loss)
% of revenue3.2%855.2%-33.6%50.1%
Attributable to non-controlling interests
Net income (loss) attributable to Fortress
% of revenue-2.5%688.2%-24.5%33.2%
Preferred A dividends declared and paid and/or cumulated, and Fortress' share of subsidiary deemed dividends
Net income (loss) attributable to common stockholders
Net income (loss) per common share attributable to common stockholders - basic
Net income (loss) per common share attributable to common stockholders - diluted—